Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBITDA (2016 - 2025)

Historic EBITDA for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to $15.2 million.

  • Anaptysbio's EBITDA rose 14787.7% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.3 million, marking a year-over-year increase of 4749.77%. This contributed to the annual value of -$144.1 million for FY2024, which is 944.96% up from last year.
  • Per Anaptysbio's latest filing, its EBITDA stood at $15.2 million for Q3 2025, which was up 14787.7% from -$38.8 million recorded in Q2 2025.
  • Over the past 5 years, Anaptysbio's EBITDA peaked at $15.2 million during Q3 2025, and registered a low of -$46.5 million during Q2 2024.
  • Over the past 5 years, Anaptysbio's median EBITDA value was -$35.6 million (recorded in 2022), while the average stood at -$29.4 million.
  • As far as peak fluctuations go, Anaptysbio's EBITDA plummeted by 677874.49% in 2022, and later skyrocketed by 14787.7% in 2025.
  • Quarter analysis of 5 years shows Anaptysbio's EBITDA stood at -$32.8 million in 2021, then increased by 21.7% to -$25.7 million in 2022, then plummeted by 58.5% to -$40.7 million in 2023, then soared by 45.3% to -$22.2 million in 2024, then surged by 168.2% to $15.2 million in 2025.
  • Its EBITDA was $15.2 million in Q3 2025, compared to -$38.8 million in Q2 2025 and -$39.5 million in Q1 2025.